



Innovating for
affordable healthcare

Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs

"Shilpa House" # 12-6-214/A1, Hyderabad Road,
RAICHUR - 584 135. Karnataka, India.

Phone : +91-8532 - 238704, Fax : +91-8532-238876

E-mail : info@vbshilpa.com Website : www.vbshilpa.com

GST NO : 29AADCS8788F1Z0

CIN No. U85110KA1987PLC008739

Date: 13.08.2019

To
Corporate Relationship Department
BSE Limited
1st Floor, rotunda Building,
P.J. Towers, Dalal Street,
Mumbai- 400 001.

To
National stock exchange India Limited,
Exchange Plaza,
Plot No. C/1, G block
Bandra Kurla Complex
Mumbai- 400 051

Dear Sir,

Sub: Reg 30: Outcome of Board meeting- Reg.
Reg: Financial results- Reg
Ref: Regulation 30 of SEBI (LODR) regulations, 2015.



Innovating for
affordable healthcare

Shilpa Medicare Limited

Registered office : # 12-6-214/A-1, Hyderabad Road, Raichur -584135

Website - www.vbshilpa.com, Email - info@vbshilpa.com, Telephone -+91-8532-238494

CIN No. - L85110KA1987PLC008739

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019

(Rs. In Lakhs, except per equity
share data)

Sl No.	Particulars	Quarter ended		Year Ended	
		30.06.2019	31.03.2019	30.06.2018	31.03.2019
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income				
	Revenue from operations	16,099.11	19,951.82	19,816.54	73,338.77
	Other Income	198.26	309.43	435.89	1,373.74
	Total Income	16,297.37	20,261.25	20,252.43	74,712.51
2	Expenses				
	a) Cost of material consumed	7,461.42	5,014.52	8,136.01	24,911.84
	b) Purchase of stock-in-trade	9.82	302.87	123.78	723.44
	c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(2,091.31)	2,157.87	(1,207.74)	22.02

Notes:

- 1 The above unaudited standalone and consolidated financial results for the quarter ended June 30, 2019 in respect of Shilpa Medicare Limited ("the Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 13, 2019.
- 2 These financial results have been prepared in accordance with Indian Accounting Standards ('Ind-AS') notified under section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Other Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016.
- 3 Effective April 1, 2019, the Company has adopted Ind AS 116 "Leases", applied to all lease contracts existing on April 1, 2019 using the modified retrospective method with practical expedient. There is no impact on retained earnings, on the date of initial application. Accordingly, comparatives for the year ended 31 March 2019 have not been retrospectively adjusted. The effect of this adoption did not have a material impact on the results for the quarter ended June 30, 2019
- 4 The Operating segment of the Company is " Pharmaceuticals", as the Chief Operating Decision Maker review business performance at the overall Company level as one segment. Therefore, segment reporting as per Ind-AS 108 is not applicable to the Company.
- 5 The results for the quarter ended June 30, 2019 presented were subjected to a " Limited review" by the Statutory Auditors of the Company. An unqualified report was issued by them thereon.



Brahmanya & Co.,

CHARTERED ACCOUNTANTS

VIJAYAWADA, HYDERABAD, VISAKHAPATNAM, GUNTUR, KAKINADA, TANUKU, ALSO AT CHENNAI, BANGALORE, MADRASI

Limited Review Report – Standalone Financial Results

To the Board of Directors of Shilpa Medicare Limited,

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of SHILPA



CHARTERED ACCOUNTANTS

VIJAYAWADA, HYDERABAD, VISAKHAPATNAM, GUNTUR, KAKINADA, TANUKU, ALSO AT CHENNAI, BANGALORE AND ADONI.

Limited Review Report – Consolidated Financial Results

To the Board of Directors of Shilpa Medicare Limited,

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of SHILPA MEDICARE LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as 'the Group'), and its share of the net profit after tax and total comprehensive income of its associates and joint Venture for the quarter ended 30th June, 2019 (the "statement"), being submitted by the parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review, Engagement (SRF) 2410, Review of Interim Financial information performed by the Independent Auditor of the Entity, issued by Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and



Brahmayya & Co.,

CHARTERED ACCOUNTANTS